Follow Us:
Cilostazol Exporter From India

Cilostazol

Cilostazol is an antiplatelet and vasodilator medication used to relieve symptoms of intermittent claudication, a condition associated with peripheral arterial disease that causes leg pain during walking. It works by inhibiting phosphodiesterase type III (PDE3), increasing cyclic AMP levels, reducing platelet aggregation and helping improve blood flow. Cilostazol is available as oral tablets, commonly in 50 mg and 100 mg strengths. Common side effects include headache, diarrhoea, abnormal stools and palpitations. It may also cause dizziness, a rapid heartbeat or low blood pressure. Cilostazol is contraindicated in patients with heart failure of any severity and requires medical supervision because of potential bleeding risks and interactions with other medicines.

  • Dosage Form:
  • Dosage Strength:
  • Manufacturer:
  • CAS No.:
  • Status:

Applications of Cilostazol

Cilostazol was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

is okay

Contraindication of Cilostazol

Availability of Cilostazol

Delivery of Cilostazol

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Cilostazol.

The is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Cilostazol.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Cilostazol, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Cilostazol Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Cilostazol

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Cilostazol Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Cilostazol, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Cilostazol

The export of Cilostazol from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Cilostazol Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Cilostazol specifications, certificates of analysis, and other supporting documents required for Cilostazol export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Cilostazol export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Cilostazol regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Cilostazol documentation, labelling, Cilostazol manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Cilostazol Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Cilostazol, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.